Nutex Health (NASDAQ:NUTX) Stock Price Up 8.1% - Still a Buy?

Nutex Health Inc. (NASDAQ:NUTX - Get Free Report)'s share price shot up 8.1% during trading on Monday . The company traded as high as $130.00 and last traded at $128.02. 73,546 shares were traded during mid-day trading, a decline of 15% from the average session volume of 86,986 shares. The stock had previously closed at $118.37.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on NUTX shares. Benchmark upped their target price on Nutex Health from $150.00 to $300.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Wall Street Zen downgraded shares of Nutex Health from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 22nd. Finally, Maxim Group increased their target price on shares of Nutex Health from $100.00 to $225.00 and gave the stock a "buy" rating in a research report on Tuesday, May 20th.

Nutex Health Trading Up 4.4%

The company has a debt-to-equity ratio of 1.02, a quick ratio of 2.26 and a current ratio of 2.27. The company's 50 day moving average is $134.51 and its 200 day moving average is $87.17. The stock has a market capitalization of $687.41 million, a price-to-earnings ratio of 10.55 and a beta of -0.04.

Nutex Health (NASDAQ:NUTX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported $2.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $2.71. Nutex Health had a net margin of 10.76% and a return on equity of 42.08%. The firm had revenue of $211.79 million during the quarter, compared to analyst estimates of $81.09 million.

Insider Buying and Selling

In related news, CFO Jon Christian Bates purchased 1,000 shares of Nutex Health stock in a transaction dated Tuesday, April 8th. The shares were acquired at an average cost of $81.81 per share, for a total transaction of $81,810.00. Following the transaction, the chief financial officer directly owned 4,888 shares of the company's stock, valued at approximately $399,887.28. This trade represents a 25.72% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 36.92% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nutex Health

A number of hedge funds and other institutional investors have recently made changes to their positions in NUTX. Goldman Sachs Group Inc. boosted its holdings in Nutex Health by 17.9% during the first quarter. Goldman Sachs Group Inc. now owns 18,119 shares of the company's stock worth $852,000 after purchasing an additional 2,748 shares during the last quarter. Jane Street Group LLC bought a new position in Nutex Health in the 1st quarter valued at about $522,000. OMERS ADMINISTRATION Corp lifted its holdings in Nutex Health by 28.8% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 9,400 shares of the company's stock worth $442,000 after purchasing an additional 2,100 shares during the last quarter. American Century Companies Inc. boosted its position in shares of Nutex Health by 73.0% in the first quarter. American Century Companies Inc. now owns 74,359 shares of the company's stock valued at $3,497,000 after acquiring an additional 31,366 shares during the period. Finally, Informed Momentum Co LLC acquired a new position in shares of Nutex Health during the 1st quarter worth approximately $868,000. 5.32% of the stock is currently owned by institutional investors and hedge funds.

About Nutex Health

Nutex Health Inc operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.